RESMED INC - FACILITY EXPECTED TO HIRE MORE THAN 100 EMPLOYEES
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy RMD?
Source: moomoo
- Facility Employment: A new facility is projected to employ over 100 workers.
- Economic Impact: The establishment of this facility is expected to positively influence the local economy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMD
Wall Street analysts forecast RMD stock price to rise
11 Analyst Rating
6 Buy
5 Hold
0 Sell
Moderate Buy
Current: 258.280
Low
260.00
Averages
294.00
High
345.00
Current: 258.280
Low
260.00
Averages
294.00
High
345.00
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Disney Appoints New CEO and Earnings Highlights
- New CEO Appointment: Disney has announced that Josh D’Amaro, the current chairman of Disney Experiences, will officially succeed Bob Iger as CEO on March 18, which is expected to drive strategic execution during the company's transformation phase.
- Executive Departure: The company also revealed that Kristina Schake, senior executive vice president and chief communications officer, will depart after March 18, a move that may impact internal communications and brand image management.
- Toast Earnings Beat: Toast reported fourth-quarter earnings of 16 cents per share on February 12, exceeding the analyst consensus estimate of 13 cents, with quarterly sales of $1.633 billion also surpassing expectations of $1.620 billion, indicating strong market demand.
- ServiceNow's Strong Performance: ServiceNow reported approximately $3.57 billion in fourth-quarter revenue on January 28, beating the consensus estimate of $3.53 billion, with adjusted earnings of 92 cents per share, also above the analyst estimate of 88 cents, reflecting its ongoing growth potential.
See More
Global Sleep Health Awareness Grows but Action Lags
- Awareness of Sleep Importance: The survey reveals that 53% of respondents rank sleep as the most crucial factor for a healthy life, surpassing diet and exercise, indicating a growing recognition of sleep health, yet meaningful actions to improve it remain lacking.
- Current Sleep Quality: Over half of respondents report achieving quality sleep only four nights a week or less, highlighting significant challenges in prioritizing sleep, which necessitates effective measures to enhance overall health.
- Surge in Wearable Device Usage: The use of wearable devices for sleep tracking surged from 16% in 2025 to 53% in 2026, with 58% of users employing smartwatches, showcasing the potential of technology to elevate sleep awareness.
- Healthcare Consultation Gap: While 66% of respondents express willingness to seek medical help for sleep issues, only 23% actually do, indicating a clear opportunity for improving education and screening within the healthcare system to identify sleep problems earlier and provide necessary support.
See More
RESMED INC - FACILITY EXPECTED TO HIRE MORE THAN 100 EMPLOYEES
- Facility Employment: A new facility is projected to employ over 100 workers.
- Economic Impact: The establishment of this facility is expected to positively influence the local economy.
See More
RESMED INC TO LAUNCH NEW CENTER IN 2027, ENHANCING U.S. PRESENCE
Operational Launch: ResMed is set to begin operations in 2027, marking a significant milestone for the company.
Expansion Plans: The initiative aims to enhance ResMed's presence in the U.S. market, indicating a strategic move for growth.
See More
RESMED GROWS U.S. PRESENCE WITH NEW DISTRIBUTION CENTER IN GREENWOOD, INDIANA
Expansion of U.S. Operations: RESMED has expanded its operations in the U.S. with a new distribution center located in Greenwood, Indiana.
Strategic Location: The new facility is strategically positioned to enhance the efficiency of RESMED's distribution network across the United States.
See More
ResMed Price Target Raised to $302 by KeyBanc Following Strong Earnings
- Analyst Confidence Boost: KeyBanc Capital Markets raised ResMed's price target from $299 to $302 while maintaining an Overweight rating, reflecting increased confidence in the company's future performance.
- Earnings Beat Expectations: ResMed's Q2 fiscal 2026 revenue exceeded expectations, driven primarily by strong performance in the Masks & Accessories and Devices segments, offsetting underwhelming results from the Software as a Service (SaaS) segment.
- Gross Margin Guidance Raised: The company raised the low end of its gross margin guidance for fiscal 2026, indicating improving profitability expectations, with a current gross margin of 60.69%, which further boosts investor confidence.
- Strong Market Performance: RBC Capital Markets increased ResMed's price target from $311 to $314, highlighting double-digit revenue and earnings growth across markets, while maintaining an Outperform rating, indicating a positive outlook for shareholder returns.
See More
Disney Appoints New CEO and Earnings Highlights
- New CEO Appointment: Disney has announced that Josh D’Amaro, the current chairman of Disney Experiences, will officially succeed Bob Iger as CEO on March 18, which is expected to drive strategic execution during the company's transformation phase.
- Executive Departure: The company also revealed that Kristina Schake, senior executive vice president and chief communications officer, will depart after March 18, a move that may impact internal communications and brand image management.
- Toast Earnings Beat: Toast reported fourth-quarter earnings of 16 cents per share on February 12, exceeding the analyst consensus estimate of 13 cents, with quarterly sales of $1.633 billion also surpassing expectations of $1.620 billion, indicating strong market demand.
- ServiceNow's Strong Performance: ServiceNow reported approximately $3.57 billion in fourth-quarter revenue on January 28, beating the consensus estimate of $3.53 billion, with adjusted earnings of 92 cents per share, also above the analyst estimate of 88 cents, reflecting its ongoing growth potential.
See More
Global Sleep Health Awareness Grows but Action Lags
- Awareness of Sleep Importance: The survey reveals that 53% of respondents rank sleep as the most crucial factor for a healthy life, surpassing diet and exercise, indicating a growing recognition of sleep health, yet meaningful actions to improve it remain lacking.
- Current Sleep Quality: Over half of respondents report achieving quality sleep only four nights a week or less, highlighting significant challenges in prioritizing sleep, which necessitates effective measures to enhance overall health.
- Surge in Wearable Device Usage: The use of wearable devices for sleep tracking surged from 16% in 2025 to 53% in 2026, with 58% of users employing smartwatches, showcasing the potential of technology to elevate sleep awareness.
- Healthcare Consultation Gap: While 66% of respondents express willingness to seek medical help for sleep issues, only 23% actually do, indicating a clear opportunity for improving education and screening within the healthcare system to identify sleep problems earlier and provide necessary support.
See More
RESMED INC - FACILITY EXPECTED TO HIRE MORE THAN 100 EMPLOYEES
- Facility Employment: A new facility is projected to employ over 100 workers.
- Economic Impact: The establishment of this facility is expected to positively influence the local economy.
See More
RESMED INC TO LAUNCH NEW CENTER IN 2027, ENHANCING U.S. PRESENCE
Operational Launch: ResMed is set to begin operations in 2027, marking a significant milestone for the company.
Expansion Plans: The initiative aims to enhance ResMed's presence in the U.S. market, indicating a strategic move for growth.
See More
RESMED GROWS U.S. PRESENCE WITH NEW DISTRIBUTION CENTER IN GREENWOOD, INDIANA
Expansion of U.S. Operations: RESMED has expanded its operations in the U.S. with a new distribution center located in Greenwood, Indiana.
Strategic Location: The new facility is strategically positioned to enhance the efficiency of RESMED's distribution network across the United States.
See More
ResMed Price Target Raised to $302 by KeyBanc Following Strong Earnings
- Analyst Confidence Boost: KeyBanc Capital Markets raised ResMed's price target from $299 to $302 while maintaining an Overweight rating, reflecting increased confidence in the company's future performance.
- Earnings Beat Expectations: ResMed's Q2 fiscal 2026 revenue exceeded expectations, driven primarily by strong performance in the Masks & Accessories and Devices segments, offsetting underwhelming results from the Software as a Service (SaaS) segment.
- Gross Margin Guidance Raised: The company raised the low end of its gross margin guidance for fiscal 2026, indicating improving profitability expectations, with a current gross margin of 60.69%, which further boosts investor confidence.
- Strong Market Performance: RBC Capital Markets increased ResMed's price target from $311 to $314, highlighting double-digit revenue and earnings growth across markets, while maintaining an Outperform rating, indicating a positive outlook for shareholder returns.
See More
